Fig. 3From: Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trialSchedule of enrollment, interventions, and assessments in the SURF studyBack to article page